Researchers at University of Arizona Cancer Center used a double-pronged approach to reduce tumor growth in tissue samples of prostate cancer.

A new review article published in Genes & Diseases explores the intricate relationship between non-coding RNAs and oxidative stress in cancer progression shedding new light on the mechanisms that drive tumor development. As cancer incidence continues to rise, particularly among younger populations, researchers are uncovering key molecular interactions that could transform the landscape of targeted therapies.

Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic repair mechanisms in cancer cells by competitively binding to the active site of PARP and limiting its activity. A new review study by researchers from Sichuan University, China, outlines the molecular mechanisms of PARP inhibitors and the potential for combination therapies comprising PARP inhibitors and other anticancer drugs to improve treatment outcomes against various cancers while limiting the adverse effects.

A review in Brain Medicine unveils the potential of targeted alpha particle therapy (TAT) as an innovative and exciting breakthrough for neuroendocrine tumours (NETs). Unlike traditional beta-particle treatments, TAT delivers high-energy alpha particles to devastate tumour DNA with precision, offering hope for patients with resistant cancers. Published on 4 March 2025, this study highlights preclinical successes and clinical breakthroughs, positioning TAT as a game-changer in oncology amidst ongoing challenges.